Moderna Inc. has received a major cash infusion from the US Biomedical Advanced Research and Development Authority (BARDA) to support its COVID-19 vaccine program.
The commitment of up to $483m will help fund activities through licensure. The mRNA-1273 vaccine started a Phase I trial...






